提吉特
神经母细胞瘤
免疫疗法
癌症研究
封锁
T细胞
生物
免疫学
免疫系统
受体
细胞培养
遗传学
作者
Judith Wienke,Lindy L. Visser,Waleed M. Kholosy,Kaylee M. Keller,Marta Barisa,Evon Poon,Sophie Munnings-Tomes,Courtney Himsworth,Elizabeth Calton,Ana Isabel Enríquez Rodríguez,Ronald J. Bernardi,Femke van den Ham,Sander R. van Hooff,Yvette A.H. Matser,Michelle L. Tas,Karin P.S. Langenberg,Philip Lijnzaad,Anne L. Borst,Elisa Zappa,Francisca J Bergsma
出处
期刊:Cancer Cell
[Cell Press]
日期:2024-01-04
卷期号:42 (2): 283-300.e8
被引量:92
标识
DOI:10.1016/j.ccell.2023.12.008
摘要
Pediatric patients with high-risk neuroblastoma have poor survival rates and urgently need more effective treatment options with less side effects. Since novel and improved immunotherapies may fill this need, we dissect the immunoregulatory interactions in neuroblastoma by single-cell RNA-sequencing of 24 tumors (10 pre- and 14 post-chemotherapy, including 5 pairs) to identify strategies for optimizing immunotherapy efficacy. Neuroblastomas are infiltrated by natural killer (NK), T and B cells, and immunosuppressive myeloid populations. NK cells show reduced cytotoxicity and T cells have a dysfunctional profile. Interaction analysis reveals a vast immunoregulatory network and identifies NECTIN2-TIGIT as a crucial immune checkpoint. Combined blockade of TIGIT and PD-L1 significantly reduces neuroblastoma growth, with complete responses (CR) in vivo. Moreover, addition of TIGIT+PD-L1 blockade to standard relapse treatment in a chemotherapy-resistant Th-ALKF1174L/MYCN 129/SvJ syngeneic model induces CR. In conclusion, our integrative analysis provides promising targets and a rationale for immunotherapeutic combination strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI